Impact of sevelamer hydrochloride on serum magnesium concentrations in hemodialysis patients

Magnesium Research

Volumn 29, Issue 4, 2016, Pages 184-190

  Ikee, Ryota ^a   Toyoyama, Takayuki ^a   Endo, Toko ^a   Tsunoda, Masataka ^a   Hashimoto, Nobuo ^a  

^a H N Medic Kitahiroshima ^*  (Japan)

Author keywords

Chronic kidney disease; Hemodialysis; Magnesium; Sevelamer hydrochloride

Indexed keywords

ALBUMIN; CALCIUM; CALCIUM CARBONATE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SEVELAMER; MAGNESIUM;

ADULT; AGED; ANURIA; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; GENDER; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPOMAGNESEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PLEIOTROPY; BLOOD; CLINICAL TRIAL; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; RENAL DIALYSIS; SEVELAMER;

EID: 85011681272     PISSN: 09531424     EISSN: 19524021     Source Type: Journal    
DOI: 10.1684/mrh.2016.0410     Document Type: Article

References (31)

1. Kanbay M, Goldsmith D, Uyar ME, Turgut F, Covic A. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif 2010; 29: 280-92.
2. Sakaguchi Y, Shoji T, Hayashi T, et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care 2012; 35: 1591-7.
3. Tin A, Grams ME, Maruthur NM, et al. Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int 2015; 87: 820-7.
4. Matsuo H, Nakamura K, Nishida A, Kubo K, Nakagawa R, Sumida Y. A case of hypermagnesemia accompanied by hypercalcemia induced by a magnesium laxative in a hemodialysis patient. Nephron 1995; 71: 477-8.
5. Jung GJ, Gil HW, Yang JO, Lee EY, Hong SY. Severe hypermagnesemia causing quadriparesis in a CAPD patient. Perit Dial Int 2008; 28: 206.
6. Gonella M, Ballanti P, Della Rocca C, et al. Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients. Miner Electrolyte Metab 1988; 14: 240-5.
7. Graf H, Kovarik J, Stummvoll HK, Wolf A. Disappearance of uraemic pruritus after lowering dialysate magnesium concentration. Br Med J 1979; 2: 1478-9.
8. Pakfetrat M, Malekmakan L, Roozbeh J, Haghpanah S. Magnesium and its relationship to C-reactive protein among hemodialysis patients. Magnes Res 2008; 21: 167-70.
9. Tzanakis I, Pras A, Kounali D, et al. Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium. Nephrol Dial Transplant 1997; 12: 2036-7.
10. Ishimura E, Okuno S, Kitatani K, et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 2007; 68: 222-7.
11. Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007; 20: 237-44.
12. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014; 85: 174-81.
13. Li L, Streja E, Rhee CM, et al. Hypomagnesemia and Mortality in Incident Hemodialysis Patients. Am J Kidney Dis 2015; 66: 1047-55.
14. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium-and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999; 55: 299-307.
15. Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N. Emerging effects of sevelamer in chronic kidney disease. Kidney Blood Press Res 2013; 37: 24-32.
16. Shinzato T, Nakai S, Fujita Y, et al. Determination of Kt/V and protein catabolic rate using preand postdialysis blood urea nitrogen concentrations. Nephron 1994; 67: 280-90.
17. Shinzato T, Nakai S, Miwa M, et al. New method to calculate creatinine generation rate using pre-and postdialysis creatinine concentrations. Artif Organs 1997; 21: 864-72.
18. Wyskida K, Witkowicz J, Chudek J, Więcek A. Daily magnesium intake and hypermagnesemia in hemodialysis patients with chronic kidney disease. J Ren Nutr 2012; 22: 19-26.
19. Ikee R, Hashimoto N. Glucose-lowering effect of sevelamer hydrochloride in hemodialysis patients. Ther Apher Dial 2015; 19: 412-3.
20. Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 2016; 11: 232-44.
21. Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N. Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients. Nephrology (Carlton) 2012; 17: 225-9.
22. Mitsopoulos E, Griveas I, Zanos S, et al. Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride. Int Urol Nephrol 2005; 37: 321-8.
23. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-14.
24. Rosa-Diez G, Negri AL, Crucelegui MS, et al. Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients. Clin Kidney J 2016; 9: 481-5.
25. Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int 2002; 62: 611-9.
26. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-5.
27. Peres AT, Dalboni MA, Canziani ME, et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodial Int 2009; 13: 271-7.
28. Grober U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients 2015; 23: 8199-226.
29. Tzanakis I, Pras A, Kounali D, et al. Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium. Nephrol Dial Transplant 1997; 12: 2036-7.
30. Ishimura E, Okuno S, Kitatani K, et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 2007; 68: 222-7.
31. Alhosaini M, Walter JS, Singh S, Dieter RS, Hsieh A, Leehey DJ. Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. Am J Nephrol 2014; 39: 204-9.